Literature DB >> 16086679

Health-related consequences of overactive bladder: an economic perspective.

Teh-Wei Hu1, Todd H Wagner.   

Abstract

About 34 million people in the USA have an overactive bladder (OAB), a condition characterized by urinary urgency, with or without urinary incontinence, and usually frequency and nocturia. This condition is associated with increased health risks (e.g. urinary tract infection, falls and fall-related injuries, including broken bones), as well as admission to nursing homes and prolonged hospital stays. The annual costs associated with OAB in the community setting are >9 billion dollars, including 2.9 billion dollars for diagnosis and treatment, 1.5 billion dollars for routine care, 3.9 billion dollars for treatment of health-related consequences, and 841 million dollars in lost productivity. These cost patterns raise the possibility that treating OAB at an early stage may both improve patient care and minimize overall use of healthcare resources. However, before a thorough economic analysis of OAB can be undertaken, more data are needed about the long-term costs and the pathogenesis of OAB-related conditions.

Entities:  

Mesh:

Year:  2005        PMID: 16086679     DOI: 10.1111/j.1464-410X.2005.05654.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  17 in total

1.  Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women.

Authors:  Elizabeth J Geller; Andrea K Crane; Ellen C Wells; Barbara L Robinson; Mary L Jannelli; Christine M Khandelwal; Annamarie Connolly; Brent A Parnell; Catherine A Matthews; Julie B Dumond; Jan Busby-Whitehead
Journal:  Clin Drug Investig       Date:  2012-10-01       Impact factor: 2.859

2.  Urge incontinence: estimating environmental and obstetrical risk factors using an identical twin study.

Authors:  Tondalaya L Gamble; Hongyan Du; Peter K Sand; Sylvia M Botros; Magdalena Rurak; Roger P Goldberg
Journal:  Int Urogynecol J       Date:  2010-05-06       Impact factor: 2.894

Review 3.  Oxybutynin: past, present, and future.

Authors:  Kelly Jirschele; Peter K Sand
Journal:  Int Urogynecol J       Date:  2012-09-14       Impact factor: 2.894

4.  Prevalence of the overactive bladder among Iranian women based on the International Continence Society definition: a population-based study.

Authors:  Mohammad Reza Safarinejad
Journal:  Int Urol Nephrol       Date:  2008-06-19       Impact factor: 2.370

5.  The surgical management of the refractory overactive bladder.

Authors:  Nikhil Vasdev; Benjamin D Biles; Raveen Sandher; Tahseen S Hasan
Journal:  Indian J Urol       Date:  2010-04

6.  Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study.

Authors:  Laura T Pizzi; Amy Talati; Eric Gemmen; Naomi V Dahl; Thomas J Bunz; Peter K Sand
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  Is the prevalence of overactive bladder overestimated? A population-based study in Finland.

Authors:  Kari A O Tikkinen; Teuvo L J Tammela; Aila M Rissanen; Antti Valpas; Heini Huhtala; Anssi Auvinen
Journal:  PLoS One       Date:  2007-02-07       Impact factor: 3.240

8.  Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.

Authors:  Tondalaya Gamble; Peter Sand
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

9.  What is the prevalence of overactive bladder symptoms in a lower socioeconomic female population?: A suggestion for a study in India.

Authors:  Kaytan V Amrute; Brian Vanderbrink; Gopal H Badlani
Journal:  Indian J Urol       Date:  2007-04

10.  Medical attendance for lower urinary tract symptoms is associated with subsequent increased risk of outpatient visits and hospitalizations based on a nationwide population-based database.

Authors:  Ming-Ping Wu; Shih-Feng Weng; Ya-Wen Hsu; Jhi-Joung Wang; Hann-Chorng Kuo
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.